Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ResMed stock

Own ResMed stock in just a few minutes.

Fact checked

ResMed Inc is a medical instruments & supplies business based in the US. ResMed shares (RMD) are listed on the NYSE and all prices are listed in US Dollars. ResMed employs 7,770 staff and has a trailing 12-month revenue of around USD$3.1 billion.

How to buy shares in ResMed

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for ResMed. Find the stock by name or ticker symbol: RMD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ResMed reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of ResMed, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of ResMed. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

ResMed share price

Use our graph to track the performance of RMD stocks over time.

ResMed shares at a glance

Information last updated 2021-02-23.
52-week rangeUSD$112.5045 - USD$223.9921
50-day moving average USD$209.1268
200-day moving average USD$195.1915
Wall St. target priceUSD$214.6
PE ratio 41.7724
Dividend yield USD$1.56 (0.78%)
Earnings per share (TTM) USD$4.79

Buy ResMed shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ResMed stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is ResMed under- or over-valued?

Valuing ResMed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ResMed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ResMed's P/E ratio

ResMed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 42x. In other words, ResMed shares trade at around 42x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

ResMed's PEG ratio

ResMed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.0721. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ResMed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

ResMed's EBITDA

ResMed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1 billion.

The EBITDA is a measure of a ResMed's overall financial performance and is widely used to measure a its profitability.

ResMed financials

Revenue TTM USD$3.1 billion
Operating margin TTM 28.98%
Gross profit TTM USD$1.8 billion
Return on assets TTM 12.55%
Return on equity TTM 27.28%
Profit margin 22.6%
Book value $19.69
Market capitalisation USD$29.1 billion

TTM: trailing 12 months

Shorting ResMed shares

There are currently 1.1 million ResMed shares held short by investors – that's known as ResMed's "short interest". This figure is 0.8% up from 1.1 million last month.

There are a few different ways that this level of interest in shorting ResMed shares can be evaluated.

ResMed's "short interest ratio" (SIR)

ResMed's "short interest ratio" (SIR) is the quantity of ResMed shares currently shorted divided by the average quantity of ResMed shares traded daily (recently around 463306.38297872). ResMed's SIR currently stands at 2.35. In other words for every 100,000 ResMed shares traded daily on the market, roughly 2350 shares are currently held short.

However ResMed's short interest can also be evaluated against the total number of ResMed shares, or, against the total number of tradable ResMed shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ResMed's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 ResMed shares in existence, roughly 10 shares are currently held short) or 0.0085% of the tradable shares (for every 100,000 tradable ResMed shares, roughly 9 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ResMed.

Find out more about how you can short ResMed stock.

ResMed's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like ResMed.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

ResMed's total ESG risk score

Total ESG risk: 29.05

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and ResMed's overall score of 29.05 (as at 01/01/2019) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like ResMed is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

ResMed's environmental score

Environmental score: 7.42/100

ResMed's environmental score of 7.42 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that ResMed is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

ResMed's social score

Social score: 14/100

ResMed's social score of 14 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that ResMed is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

ResMed's governance score

Governance score: 12.64/100

ResMed's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that ResMed is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

ResMed's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. ResMed scored a 1 out of 5 for controversy – the highest score possible, reflecting that ResMed has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

ResMed Inc was last rated for ESG on: 2019-01-01.

Total ESG score 29.05
Total ESG percentile 50.28
Environmental score 7.42
Environmental score percentile 4
Social score 14
Social score percentile 4
Governance score 12.64
Governance score percentile 4
Level of controversy 1

ResMed share dividends

29%

Dividend payout ratio: 29.43% of net profits

Recently ResMed has paid out, on average, around 29.43% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.78% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ResMed shareholders could enjoy a 0.78% return on their shares, in the form of dividend payments. In ResMed's case, that would currently equate to about $1.56 per share.

While ResMed's payout ratio might seem fairly standard, it's worth remembering that ResMed may be investing much of the rest of its net profits in future growth.

ResMed's most recent dividend payout was on 18 March 2021. The latest dividend was paid out to all shareholders who bought their shares by 10 February 2021 (the "ex-dividend date").

Have ResMed's shares ever split?

ResMed's shares were split on a 2:1 basis on 31 August 2010. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ResMed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ResMed shares which in turn could have impacted ResMed's share price.

ResMed share price volatility

Over the last 12 months, ResMed's shares have ranged in value from as little as $112.5045 up to $223.9921. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while ResMed's is 0.3228. This would suggest that ResMed's shares are less volatile than average (for this exchange).

ResMed overview

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site